NCT05398198View on ClinicalTrials.gov

Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

April 9, 2024

Study Completion Date

April 9, 2024

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK3923868

GSK3923868 dose and administration as per study intervention.

DRUG

Placebo

Placebo matching GSK3923868 will be administered.

Trial Locations (1)

E1 2AX

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT05398198 - Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma | Biotech Hunter | Biotech Hunter